15-min delayed · Aug 25, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 1 firms covering Harvard Bioscience Inc, 1 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $7.50 to $7.50, so the covering firms are broadly aligned. The average target of $7.50 is roughly in line with the current $7.50. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.23 next quarter toward $0.65 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS1 ratings
Strong Buy
Strong Buy00%
Buy1100%
Hold00%
Sell00%
Strong Sell00%
Based on 1 analysts giving stock ratings to Harvard Bioscience Inc.
As of Aug, 1 of 1 firms rate HBIO a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
HBIO EPS & revenue forecast
EPS · NEXT QUARTER
$0.23
Range $0.16 – $0.30 · 2 analysts
Next period, 2 analysts expect Harvard Bioscience Inc to earn $0.23 a share (range $0.16 – $0.30), versus $0.00 a year earlier. Full-year consensus is $-0.38, growing to $0.65 the year after.
REVENUE · NEXT QUARTER
$24.5M
Range $24.5M – $24.5M · 2 analysts · +3% YoY
Revenue is expected to reach $24.5M (range $24.5M – $24.5M), +3.2% year-over-year. Full-year consensus is $89.8M, rising to $94.5M next year.
Top analysts covering Harvard Bioscience Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on HBIO.
#1
Paul Knight
Keybanc · Rank #329
Hold
No targeton HBIO
Overall win rate
35%
+ Follow
#2
Bruce Jackson
Benchmark · Rank #366
Buy
$7.50-0.1% to target
Overall win rate
36%
+ Follow
HBIO stock forecast FAQ
What is HBIO's average 12-month price target?+
The 1 analysts with a live target average $7.50 for Harvard Bioscience Inc over the next 12 months, ranging from a $7.50 high to a $7.50 low.
Is HBIO stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 1 analyst ratings, 1 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover HBIO?+
1 analysts have an active rating on Harvard Bioscience Inc, and 1 firms carry a live 12-month price target.
Who is the most accurate analyst covering HBIO?+
Among analysts who currently cover HBIO, Paul Knight of Keybanc has the strongest overall Quantellect track record (Rank #329). Their current call is Hold.
What is Harvard Bioscience Inc's projected EPS for next quarter?+
The consensus estimate is $0.23 per share (range $0.16 – $0.30) across 2 analysts. Full-year EPS is projected at $-0.38, rising to $0.65 the following year.
How much revenue is Harvard Bioscience Inc expected to report next quarter?+
Consensus revenue is $24.5M (range $24.5M – $24.5M). Full-year revenue is projected at $89.8M, growing to $94.5M next year.
Have analysts been upgrading or downgrading HBIO lately?+
As of Aug, 1 of 1 firms rate HBIO a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their HBIO calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
